Positive assessment of EMA’s activities in 2023 The Management Board assessed and adopted the Executive Director’s annual activity report for 2023. The report describes the implementation of the Agency’s work programme and the management and control …
Metamizole (also known as dipyrone) is an analgesic medicine (painkiller). It has been used in the EU since the 1920s and is taken by mouth, suppository or injection, to treat moderate to severe pain and fever. The review includes both medicines containing …
Call for scientific data for the periodic review of the monograph on Urtica dioica L. and Urtica urens L., herba Consultation dates: 01/04/2020 to 30/06/2020Draft: consultation closedReference Number: EMA/HMPC/149163/2020
The HMPC conclusions on the use of ginger medicines for the prevention of nausea and vomiting in motion sickness are based on their 'well-established use' in this indication. This means that there are bibliographic data providing scientific …
Draft Community herbal monograph on Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix - First version Consultation dates: 15/10/2011 to 15/02/2012Draft: consultation closedReference Number: EMA/HMPC/461160/2008
This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.
English (EN) (81.94 KB - PDF) First published: 27/03/2013Last updated: 13/06/2024
English (EN) (81.94 KB - PDF) First published: 10/02/2015Last updated: 13/06/2024
English (EN) (81.94 KB - PDF) First published: 14/10/2010Last updated: 13/06/2024
English (EN) (81.94 KB - PDF) First published: 14/10/2019Last updated: 13/06/2024
dinotefuran, permethrin, and pyriproxyfen
Gumbohatch : EPAR - Medicine overview Reference Number: EMA/494045/2019
The European Commission is reviewing the rules governing the procedures for post-authorisation changes to the terms of a marketing authorisation for human medicines. This concerns the Commission Regulation (EC) No 1234/2008 together with the variations …
EMA is launching a pilot to provide scientific advice to manufacturers of certain high-risk medical devices. As per Article 61(2) of Regulation (EU) 2017/745 on medical devices, the expert panels may give scientific advice to manufacturers of some high- …
EMA is in dialogue with medicine developers to gain an overview of available data on suitability of existing and potential new vaccines and treatments, and opportunities to adapt existing vaccines to match more closely the virus strains in circulation, in …
English (EN) (229.29 KB - PDF) First published: 12/06/2024
The purpose of the meeting is to exchange views and clarify modalities of industry stakeholders' interactions.
Agenda of the HMPC meeting 18-20 March 2024 DraftReference Number: EMA/HMPC/86409/2024
English (EN) (81.94 KB - PDF) First published: 18/12/2015Last updated: 11/06/2024
English (EN) (81.94 KB - PDF) First published: 23/02/2018Last updated: 11/06/2024
01 days 23:17:53
